UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

restricted population of CB₁ cannabinoid receptors with neuroprotective activity

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (22), p.8257-8262

2014

Volltextzugriff (PDF)

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

Brain (London, England : 1878), 2009-11, Vol.132 (11), p.3152-3164

2009

Volltextzugriff (PDF)

Editorial: Cannabinoids as potential treatment for neurological diseases

Frontiers in neuroscience, 2022-12, Vol.16, p.1108101-1108101

2022

Volltextzugriff (PDF)

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

Brain (London, England : 1878), 2011-01, Vol.134 (Pt 1), p.119-136

2011

Volltextzugriff (PDF)

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

Journal of neuroscience research, 2011-09, Vol.89 (9), p.1509-1518

2011

Volltextzugriff (PDF)

Retinal Tissue Shows Glial Changes in a Dravet Syndrome Knock-in Mouse Model

International journal of molecular sciences, 2023-02, Vol.24 (3), p.2727

2023

Volltextzugriff (PDF)

Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments

Frontiers in molecular neuroscience, 2021-01, Vol.13, p.602801-602801

2021

Volltextzugriff (PDF)

ANALYZING THE INFLUENCE OF CANNABIS SATIVA COMPOUNDS ON THE MYELINATION PROCESS IN A MURINE MODEL OF DRAVET SYNDROME

IBRO neuroscience reports, 2023-10, Vol.15, p.S644-S645

2023

Volltextzugriff (PDF)

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors

ACS chemical neuroscience, 2012-05, Vol.3 (5), p.400-406

2012

Volltextzugriff (PDF)

THE EFFICACY OF COMBINED TREATMENT WITH ΒETA-CARYOPHYLLENE AND CANNABIDIOL IN A MOUSE MODEL OF DRAVET SYNDROME

IBRO neuroscience reports, 2023-10, Vol.15, p.S574-S574

2023

Volltextzugriff (PDF)

EXPLORING THE MYELINATION STATUS IN A MURINE MODEL OF DRAVET SYNDROME

IBRO neuroscience reports, 2023-10, Vol.15, p.S643-S643

2023

Volltextzugriff (PDF)

Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease

Recent patents on CNS drug discovery, 2012-04, Vol.7 (1), p.41-48

2012

Volltextzugriff (PDF)

Possible therapeutic applications of cannabis in the neuropsychopharmacology field

European neuropsychopharmacology, 2020-07, Vol.36, p.217-234

2020

Volltextzugriff (PDF)

Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

Neuropharmacology, 2022-03, Vol.205, p.108914-108914, Article 108914

2022

Volltextzugriff (PDF)

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.323-333

2013

Volltextzugriff (PDF)

Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

Neuropharmacology, 2023-10, Vol.237, p.109602-109602, Article 109602

2023

Volltextzugriff (PDF)

Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Neurotherapeutics, 2015-01, Vol.12 (1), p.185-199

2015

Volltextzugriff (PDF)

Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

Biochemical pharmacology, 2018-11, Vol.157, p.85-96

2018

Volltextzugriff (PDF)

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease

International journal of molecular sciences, 2017-04, Vol.18 (4), p.684-684

2017

Volltextzugriff (PDF)

Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1a WT/A1783V mice, a preclinical model of Dravet syndrome

Neuropharmacology, 2023-10, Vol.237, p.109602

2023

Volltextzugriff (PDF)

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

Journal of neurology, 2016-07, Vol.263 (7), p.1390-1400

2016

Volltextzugriff (PDF)

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

The European journal of neuroscience, 2007-08, Vol.26 (4), p.843-851

2007

Volltextzugriff (PDF)

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

Glia, 2009-08, Vol.57 (11), p.1154-1167

2009

Volltextzugriff (PDF)

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy

Journal of Alzheimer's disease, 2013-01, Vol.35 (3), p.525-539

2013

Volltextzugriff (PDF)

Therapeutic potential of the endocannabinoid system in the brain

Mini reviews in medicinal chemistry, 2005-07, Vol.5 (7), p.609-617

2005

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Animals
(20)
Neurosciences
(16)
Neurosciences & Neurology
(16)
Neuroprotection
(13)
Cannabinoids
(12)
Male
(12)
Mice
(12)
Pharmacology & Pharmacy
(11)
Cannabidiol
(10)
Humans
(10)
Huntington's Disease
(10)
Cannabinoids - Pharmacology
(8)
Disease Models, Animal
(7)
Neuroprotective Agents - Pharmacology
(7)
Rats
(7)
Huntington Disease - Drug Therapy
(6)
Neurodegeneration
(6)
Neurology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

restricted population of CB₁ cannabinoid receptors with neuroprotective activity

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

Editorial: Cannabinoids as potential treatment for neurological diseases

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

Retinal Tissue Shows Glial Changes in a Dravet Syndrome Knock-in Mouse Model

Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments

ANALYZING THE INFLUENCE OF CANNABIS SATIVA COMPOUNDS ON THE MYELINATION PROCESS IN A MURINE MODEL OF DRAVET SYNDROME

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors

THE EFFICACY OF COMBINED TREATMENT WITH ΒETA-CARYOPHYLLENE AND CANNABIDIOL IN A MOUSE MODEL OF DRAVET SYNDROME

EXPLORING THE MYELINATION STATUS IN A MURINE MODEL OF DRAVET SYNDROME

Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease

Possible therapeutic applications of cannabis in the neuropsychopharmacology field

Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease

Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1a WT/A1783V mice, a preclinical model of Dravet syndrome

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy

Therapeutic potential of the endocannabinoid system in the brain

Suchergebnisse filtern